1 suspended, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Suspended 1, Unknown 1 |
Follow JS InnoPharm, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ERK Inhibitor JSI-1187 in Advanced Solid Tumors JSI-1187 - Solid Tumor, NSCLC | Phase 1 | Unknown | JS InnoPharm, LLC | 60 | 2022-04-02 | 2024-02-02 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1)
dabrafenib (1)
China (1) · United States (1)
Lin Shen, PhD (1)